The short answer is yes. ARQL's tivantinib has shown to be active in multiple indications. The 2nd-line, HCC Phase 2 results are compelling. Given that it was a randomized, double-blind trial, i'm hoping the results can be replicated in the phase 3, however, it is going to be a long wait with few new catalysts (mCRC) to drive the stock in the near-term.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.